FDA Determines Regulatory Review Period for SKINVIVE Medical Device
May 14, 2025
May 14, 2025
WASHINGTON, May 14 (TNSFR) -- The U.S. Department of Health and Human Services Food and Drug Administration has announced its determination regarding the regulatory review period for the medical device SKINVIVE, which was submitted for patent term extension.
This decision follows an application made to the U.S. Patent and Trademark Office (USPTO) by Allergan Industrie, SAS, for extending the patent for SKINVIVE under U.S. Patent No. 11,260,015. SKINVIVE, which was approved by the FD . . .
This decision follows an application made to the U.S. Patent and Trademark Office (USPTO) by Allergan Industrie, SAS, for extending the patent for SKINVIVE under U.S. Patent No. 11,260,015. SKINVIVE, which was approved by the FD . . .